Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Cocrystal Pharma, Inc.

Market Cap 13.93M 12.08M 11.14M 10.44M 19.5M 1.33B 19.91M 133M 51.45M 643M 52.28M 51.15M 2.23B P/E Ratio 2026 *
-1.47x
P/E Ratio 2027 * -1.58x
Enterprise Value 13.93M 12.08M 11.14M 10.44M 19.5M 1.33B 19.91M 133M 51.45M 643M 52.28M 51.15M 2.23B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
69.27%
Yield 2026 *
-
Yield 2027 * -
1 day+1.00%
1 week-3.81%
Current month-9.82%
1 month-22.31%
3 months-1.94%
6 months-4.72%
Current year+3.17%
1 week 0.97
Extreme 0.9699
1.08
1 month 0.95
Extreme 0.95
1.3
Current year 0.86
Extreme 0.8588
2.03
1 year 0.86
Extreme 0.8588
2.67
3 years 0.86
Extreme 0.8588
3.28
5 years 0.86
Extreme 0.8588
17.88
10 years 0.86
Extreme 0.8588
220.32
Manager TitleAgeSince
Chief Executive Officer 64 2026-06-02
Chief Executive Officer 59 2021-05-26
Chief Executive Officer 66 2021-05-26
Director TitleAgeSince
Director/Board Member 88 2014-01-01
Chairman 79 2021-05-26
Director/Board Member 65 2014-01-01
Date Insider Type Main position Quantity % Market Cap.
Jun. 02Free

Chief Executive Officer

235,000 1.7044%
Feb. 23Buy

Director

20,000 0.1451%
Feb. 05Buy

Director

50,000 0.3627%
Change 5-day change 1-year change 3-year change Capi.($)
+1.00%-3.81%-38.41%-60.85% 13.79M
+1.65%+6.42%+53.16%+112.78% 54.82B
+0.03%+0.33%+49.22%+43.94% 43.27B
+3.93%-0.06%-15.10%-18.04% 21.79B
+5.27%-7.82%-1.29%+388.48% 19.92B
-0.13%-8.43%+8.04%-32.02% 15.67B
+0.53%+2.08%+8.89%-39.59% 15.26B
+1.75%+1.92%+29.13%+178.65% 13.22B
+5.27%+5.49%+14.20% - 11.94B
-5.27%-0.43%+87.77%+208.02% 11.58B
Average +1.42%-0.86%+19.56%+86.82% 20.75B
Weighted average by Cap. +1.53%+0.64%+31.43%+97.64%

Financials

2026 *2027 *
Net sales - -
Net income -10.5M -9.11M -8.4M -7.87M -14.7M -1.01B -15.01M -100M -38.79M -485M -39.42M -38.57M -1.69B -11.5M -9.98M -9.2M -8.62M -16.1M -1.1B -16.44M -110M -42.49M -531M -43.17M -42.24M -1.85B
Net Debt - -
Logo Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses (HCV). It is developing small molecule antiviral therapeutics that inhibit the essential viral replication function of RNA viruses, causing acute and chronic viral diseases. It has several candidates under development for the treatment of influenza infection. CC-42344 is a novel PB2 inhibitor, which is a preclinical lead for the treatment of pandemic and seasonal influenza A. It also develops broad-spectrum influenza antivirals targeting replication enzymes of influenza A and B strains. Its broad-spectrum antiviral drug candidate, CDI-988, is an oral treatment for SARS-CoV-2, the virus that causes COVID-19. Its CC-31244, an HCV NNI, is a pan-genotypic inhibitor of NS5B polymerase for the treatment of HCV.
Employees
10
Date Price Change Volume
26-06-11 1.010 $ +1.00% 30,344
26-06-10 1.000 $ -1.96% 50,041
26-06-09 1.020 $ +0.99% 65,530
26-06-08 1.010 $ +4.74% 40,128
26-06-05 0.9643 $ -8.16% 160,196
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.010USD
Average target price
8.000USD
Spread / Average Target
+692.08%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. COCP Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!